Back to Agenda
Session 4: The Drive Towards Pragmatism in Randomized Clinical Trials: Are We There Yet?
Session Chair(s)
James Harnett, PHARMD, MS
Executive Director, Health Economics and Outcomes Research, Regeneron Pharmaceuticals, Inc. , United States
Debra Schaumberg, DRSC, MPH
Vice President and Global Head, Startegic Development Consulting Chair, Evidera | PPD, United States
Learning Objective : At the conclusion of this session, participants should be able to:- Describe the dimensions of pragmatism that can be considered in designing randomized clinical trials
- Discuss relevant examples of PCTs to support healthcare decision-making
- Identify challenges with PCTs and opportunities to address
Speaker(s)
Mark J Cziraky, PHARMD
Vice President of Research, Anthem HealthCore, United States
Getting to Value
Frank W. Rockhold, PHD, MSC
Professor of Biostatistics, Duke Clinical Research Institute, Duke University Medical Center, United States
The Drive Towards Pragmatism in Randomized Clinical Trials: Are We There Yet?
Have an account?